Hamza Hashmi

2.5k total citations
102 papers, 476 citations indexed

About

Hamza Hashmi is a scholar working on Oncology, Hematology and Molecular Biology. According to data from OpenAlex, Hamza Hashmi has authored 102 papers receiving a total of 476 indexed citations (citations by other indexed papers that have themselves been cited), including 61 papers in Oncology, 61 papers in Hematology and 36 papers in Molecular Biology. Recurrent topics in Hamza Hashmi's work include Multiple Myeloma Research and Treatments (48 papers), CAR-T cell therapy research (41 papers) and Protein Degradation and Inhibitors (17 papers). Hamza Hashmi is often cited by papers focused on Multiple Myeloma Research and Treatments (48 papers), CAR-T cell therapy research (41 papers) and Protein Degradation and Inhibitors (17 papers). Hamza Hashmi collaborates with scholars based in United States, Pakistan and Jordan. Hamza Hashmi's co-authors include James A. Davis, Al‐Ola Abdallah, Nausheen Ahmed, Joseph P. McGuirk, Faiz Anwer, Jack Khouri, Danai Dima, Leyla Shune, Shahzad Raza and Taiga Nishihori and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Hamza Hashmi

88 papers receiving 472 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hamza Hashmi United States 11 274 198 177 76 44 102 476
Zahra Mahmoudjafari United States 10 304 1.1× 163 0.8× 126 0.7× 56 0.7× 26 0.6× 75 449
Leyla Shune United States 13 410 1.5× 343 1.7× 210 1.2× 99 1.3× 90 2.0× 107 688
Asmita Mishra United States 15 234 0.9× 411 2.1× 187 1.1× 72 0.9× 123 2.8× 63 672
David Beauvais France 10 168 0.6× 97 0.5× 95 0.5× 41 0.5× 42 1.0× 39 329
Odelia Amit Israel 13 278 1.0× 167 0.8× 92 0.5× 59 0.8× 44 1.0× 39 525
Keith J. August United States 14 408 1.5× 230 1.2× 166 0.9× 124 1.6× 61 1.4× 50 799
Sai Ravi Pingali United States 14 212 0.8× 167 0.8× 95 0.5× 109 1.4× 64 1.5× 63 529
Philip Imus United States 12 231 0.8× 361 1.8× 66 0.4× 220 2.9× 58 1.3× 40 583
Elham Askari Iran 10 345 1.3× 321 1.6× 252 1.4× 115 1.5× 38 0.9× 29 651
Swetha Kambhampati United States 11 196 0.7× 83 0.4× 101 0.6× 72 0.9× 13 0.3× 29 424

Countries citing papers authored by Hamza Hashmi

Since Specialization
Citations

This map shows the geographic impact of Hamza Hashmi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hamza Hashmi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hamza Hashmi more than expected).

Fields of papers citing papers by Hamza Hashmi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hamza Hashmi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hamza Hashmi. The network helps show where Hamza Hashmi may publish in the future.

Co-authorship network of co-authors of Hamza Hashmi

This figure shows the co-authorship network connecting the top 25 collaborators of Hamza Hashmi. A scholar is included among the top collaborators of Hamza Hashmi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hamza Hashmi. Hamza Hashmi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Davis, James A., Danai Dima, Nausheen Ahmed, et al.. (2024). Impact of Frailty on Outcomes after CAR T-Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma. Transplantation and Cellular Therapy. 30(2). S195–S196. 1 indexed citations
2.
Shaikh, Hira, James A. Davis, Nausheen Ahmed, et al.. (2024). P-079 Real-World Safety and Efficacy of Talquetamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 24. S87–S88. 1 indexed citations
3.
Shaikh, Hira, Christopher Strouse, James A. Davis, et al.. (2024). Real-World Efficacy Outcomes of Ciltacabtagene Autoleucel in Relapsed Refractory Multiple Myeloma: A Comparative Study with the Cartitude-1 Trial. Blood. 144(Supplement 1). 2411.2–2411.2. 1 indexed citations
4.
Dima, Danai, Razan Mansour, James A. Davis, et al.. (2024). Efficacy and safety of daratumumab, pomalidomide, and dexamethasone versus daratumumab, carfilzomib, and dexamethasone in daratumumab‐naïve relapsed multiple myeloma. European Journal Of Haematology. 112(6). 975–983. 2 indexed citations
5.
Davis, James A., et al.. (2024). “Fast but not so furious”: A condensed step‐up dosing schedule of teclistamab for relapsed/refractory multiple myeloma. SHILAP Revista de lepidopterología. 5(4). 793–797. 1 indexed citations
6.
Hashmi, Hamza, Ambuj Kumar, Mohamed A. Kharfan‐Dabaja, et al.. (2024). ASTCT Committee on Practice Guidelines Survey on Evaluation and Management of Relapsed/Refractory Multiple Myeloma after Failure of Chimeric Antigen Receptor T Cell Therapy. Transplantation and Cellular Therapy. 30(8). 750–759. 1 indexed citations
7.
Ahmed, Nausheen, Anuj Shrestha, Faiz Anwer, et al.. (2024). TACTUM: Trends in Access to Cellular Therapies in Multiple Myeloma, Perspectives of Treating Versus Referring Physicians. Transplantation and Cellular Therapy. 30(9). 925.e1–925.e6. 2 indexed citations
8.
Dima, Danai, James A. Davis, Leyla Shune, et al.. (2024). Efficacy and safety of idecabtagene vicleucel in patients with relapsed–refractory multiple myeloma not meeting the KarMMa‐1 trial eligibility criteria: A real‐world multicentre study. British Journal of Haematology. 204(4). 1293–1299. 10 indexed citations
9.
Davis, James A., Danai Dima, Nausheen Ahmed, et al.. (2023). Impact of Frailty on Outcomes after Chimeric Antigen Receptor T Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma. Transplantation and Cellular Therapy. 30(3). 298–305. 18 indexed citations
10.
11.
Davis, James A., Danai Dima, Nausheen Ahmed, et al.. (2023). Impact of Frailty on Outcomes after CAR T-Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma. Blood. 142(Supplement 1). 3503–3503. 2 indexed citations
12.
Oluwole, Olalekan O., Bhagirathbhai Dholaria, Tristan Knight, et al.. (2023). Chimeric Antigen Receptor T-Cell Therapy in the Outpatient Setting: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Transplantation and Cellular Therapy. 30(2). 131–142. 17 indexed citations
13.
Davis, James A., Douglas W. Sborov, Al‐Ola Abdallah, et al.. (2023). Efficacy and Safety of CD34+ Stem Cell Boost for Delayed Hematopoietic Recovery After BCMA Directed CAR T-cell Therapy. Transplantation and Cellular Therapy. 29(9). 567–571. 27 indexed citations
14.
Ehsan, Hamid, et al.. (2022). Efficacy and safety of selinexor-based regimens for relapsed/refractory multiple myeloma: a systematic review of literature. Annals of Hematology. 101(12). 2601–2610. 2 indexed citations
15.
16.
Ehsan, Hamid, et al.. (2022). Treatment of Light Chain Deposition Disease: A Systematic Review. Journal of Hematology. 11(4). 123–130. 7 indexed citations
17.
Davis, James A., et al.. (2022). Chimeric Antigen Receptor T-Cell (CAR T-Cell) Therapy for Primary and Secondary Central Nervous System Lymphoma: A Systematic Review of Literature. Clinical Lymphoma Myeloma & Leukemia. 23(1). 15–21. 6 indexed citations
18.
O’Donnell, Paul V., Claudio G. Brunstein, Ephraim J. Fuchs, et al.. (2021). Umbilical Cord Blood or HLA-Haploidentical Transplantation: Real-World Outcomes versus Randomized Trial Outcomes. Transplantation and Cellular Therapy. 28(2). 109.e1–109.e8. 10 indexed citations
19.
Ehsan, Hamid, et al.. (2021). Efficacy and Safety of Daratumumab-based Regimens in Pretreated Light Chain (AL) Amyloidosis: A Systematic Review. Clinical Lymphoma Myeloma & Leukemia. 22(5). e285–e292. 1 indexed citations
20.
Hashmi, Hamza, et al.. (2017). Use of a Hemoglobin Substitute (HBOC-201) to Treat Acute Anemia in a Leukemic Patient with Anti-Vel Antibodies. Blood. 130. 4928–4928. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zahra Mahmoudjafari Breakdown of academic impact, for papers by Leyla Shune Breakdown of academic impact, for papers by Asmita Mishra Breakdown of academic impact, for papers by David Beauvais Breakdown of academic impact, for papers by Odelia Amit Breakdown of academic impact, for papers by Keith J. August Breakdown of academic impact, for papers by Sai Ravi Pingali Breakdown of academic impact, for papers by Philip Imus Breakdown of academic impact, for papers by Elham Askari Breakdown of academic impact, for papers by Swetha Kambhampati
Rankless by CCL
2026